Increasing Transparency - Transfers of Value to Healthcare Professionals and Organisations
Novartis collaborates with Healthcare Professionals and Healthcare Organisations to advance patient care and is committed to openly communicating transfers of value related to these relationships.
Collaborative working between healthcare professionals and pharmaceutical companies has long been a driver for advancements in patient care and innovative medicine.
Both parties regularly collaborate during early scientific research, clinical trials and medical education in the interest of delivering and advancing high quality patient care.
From 2016 the Irish pharmaceutical industry* will make public details of certain transfers of value (i.e. payments/benefits in kind) made to healthcare professionals, and their organisations, for various collaborations that take place from 2015 onwards.
In order to adhere to data protection laws, Healthcare Practitioners must give consent for individual (ie named) data to be disclosed. In the absence of this consent, the data will be published in aggregate form. In the interest of greater transparency, Novartis and the Irish Pharmaceutical Healthcare Association (IPHA) is urging HCPs to grant such consent.
Novartis fully supports this Europe-wide initiative, led by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and IPHA.
Collaboration At Novartis Ireland, we believe that innovation can have an significant impact on medicine, science and humankind. We are committed to listening, and engaging in trusting and mutually successful collaborative partnerships. We are constantly looking for partners to advise us, and who want to share the journey with us. In Ireland, we greatly appreciate the collaboration of our pharma Industry Council We believe the best innovation comes from the practice of shoulder-to-shoulder, curious and inspired and collaboration.